{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.57","value":"-1.8"},{"groupId":"OG001","spread":"5.01","value":"-5.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"description":"The ASQoL is a self-administered health-related quality of life (HRQOL) instrument. It consists of 18 items requesting a Yes or No response to questions related to the impact of the disease/condition (including pain) on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. A score of 1 is given to a response of \"yes\" on each item and all item scores are summed to a total score with a range of 0 to 18. Higher scores indicate worse HRQOL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received placebo intravenous (IV) infusions at Weeks 0, 4, and 12. At Week 16 participants were crossed over to golimumab and received IV golimumab 2 mg/kg infusions at Weeks 16, 20, and every 8 weeks (q8w) thereafter through Week 52.","id":"OG000","title":"Group 1: Placebo Then Golimumab"},{"description":"Participants received IV golimumab 2 mg/kg infusion at Weeks 0, 4 and then q8w thereafter through Week 52. Participants received a placebo infusion at Week 16 to maintain the treatment blind.","id":"OG001","title":"Group 2: Golimumab"}],"paramType":"MEAN","populationDescription":"FAS included all participants who were randomized in the study. Here, 'N' (Number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 16","title":"Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 16","type":"SECONDARY","unitOfMeasure":"Units on Scale"}